The bill reduces uncertainty and strengthens patent protection for many inventors (especially in software and biotech) by clarifying eligibility rules, but it increases the risk that broader or lower-quality patents will survive—raising litigation, costs, competitive concentration, and potential access issues for medical innovations.
Inventors, the USPTO, and courts get clearer statutory rules on patent eligibility, reducing legal uncertainty and inconsistent rulings for many kinds of inventions.
Clearer guidance for software- and machine-implemented inventions preserves eligibility for genuine machine-dependent innovations while setting clearer limits to curb low-quality software patents.
Biotech inventors can obtain stronger protection for purified, enriched, or modified biological materials while unmodified human genes and natural materials are explicitly excluded, which supports biotech investment while protecting some research access.
Broadening §101 eligibility and limiting consideration of §§102/103/112 in eligibility determinations could let low-quality or obvious patents survive, increasing litigation, licensing costs, and burdens on businesses and consumers.
Stronger protections for software- and business-related inventions may entrench dominant firms, reduce competition, and lead to higher prices for consumers and barriers for smaller competitors.
Allowing patents on modified, purified, or enriched biological materials while excluding only unmodified genes risks higher costs or restricted access to medical tests and therapies for patients.
Based on analysis of 4 sections of legislative text.
Introduced May 1, 2025 by Kevin Kiley · Last progress May 1, 2025
Rewrites federal patent-eligibility law to broaden what counts as patentable subject matter while listing explicit categories that remain ineligible. It eliminates judicially created exceptions, updates statutory definitions (including a new definition of “useful”), clarifies that patentability questions must be decided by looking at the claimed invention as a whole, and limits courts from relying on novelty, nonobviousness, or disclosure rules to deny eligibility. The change also lists specific exclusions (pure mathematical formulas, purely mental processes, unmodified human genes and natural materials, and largely economic/financial/business/social/cultural/artistic processes) and says inventions that cannot practically be performed without a machine remain eligible even if they involve those areas.